AI-assisted research analysis by FutureKnowledge. Sources checked 3 November 2026. This is not investment advice.
Reviewed by FutureKnowledge: figures, dates and attributions were checked against the linked sources before publication.
Pfizer raised its 2026 revenue guidance to $62 billion to $64 billion on Tuesday after third-quarter adjusted earnings of $0.87 a share beat the roughly $0.73 analysts expected, even though quarterly sales were essentially flat at $16.58 billion. The results show a company whose newer medicines are growing quickly enough to offset a steep fall in COVID-19 product sales, but not yet quickly enough to lift the top line.
Pfizer Q3 results: what the numbers show
According to Pfizer’s results release, revenue for the quarter was $16,583 million against $16,654 million a year earlier, a decline of $71 million. Reported net income fell 8% to $3,242 million and reported diluted earnings per share fell 9% to $0.56. Adjusted net income rose 1% to $4,985 million, leaving adjusted EPS unchanged from a year earlier at $0.87.
The beat was large relative to expectations. StockStory put consensus at $15.85 billion for revenue and $0.73 for adjusted EPS, implying beats of about 4.6% and 19%. Grafa cited the same $0.73 EPS consensus. A pre-results preview by Pomegra noted that estimates had been cut by about 10% over the previous 90 days, which partly explains why an unchanged year-on-year EPS figure counted as a large beat.
The quarter’s adjusted EPS also absorbed roughly $0.10 a share from a one-time $650 million acquired research charge linked to Pfizer’s in-licensing deal with Innovent Biologics, as noted in the release and by Rallies.
Raised 2026 guidance
| Metric | Previous 2026 guidance | New 2026 guidance |
|---|---|---|
| Revenue | $60.5bn to $62.5bn | $62.0bn to $64.0bn |
| Adjusted diluted EPS | $2.80 to $3.00 | $2.95 to $3.05 |
| Adjusted R&D expenses | $10.5bn to $11.5bn | $10.8bn to $11.8bn |
The revenue midpoint moves up by $1.5 billion to $63 billion, which StockStory said is about 1.2% above the analyst consensus. The guidance still assumes about $1.1 billion of revenue lost to generic and biosimilar competition this year, no share buybacks and no unannounced deals, according to the release.
Why revenue stood still: COVID down, newer drugs up
The flat headline hides two opposing trends. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. Revenue from launched and acquired products rose 32% operationally to about $3.8 billion, led by Padcev, Nurtec and Lorbrena, per the release and Rallies.
Against that, Paxlovid sales fell $771 million, or 63% operationally, which Pfizer attributed mainly to lower infection levels. Comirnaty fell $339 million, or 29%, citing a smaller favourable returns adjustment than last year and narrower US vaccination recommendations.
Biggest product movers in Q3 (operational change)
- Eliquis: up $513 million (+25%), mainly on US net price, with generic erosion in some international markets.
- Padcev: up $255 million (+55%).
- Vyndaqel family: up $193 million (+12%).
- Nurtec ODT/Vydura: up $135 million (+33%).
- Lorbrena: up $114 million (+43%).
- Prevnar family: down $180 million (-10%), on lower US vaccination rates and adult share loss.
Pfizer’s new chief financial officer, Cecile Guegan, who took the role on 1 November, highlighted the 7% non-COVID growth. Chief executive Albert Bourla described the quarter as showing “commercial momentum and disciplined execution.”
How it affects businesses and investors
The market reaction was muted. StockStory reported the shares fell about 1.1% to $30.48 immediately after the release, giving Pfizer a market value of roughly $175 billion. Pomegra noted the stock had already risen about 22% over three months to near its 52-week high going into the report, so much of the improvement may have been anticipated.
The bigger question for Pfizer remains the patent cliff later this decade. Pomegra notes that Eliquis, Ibrance and Xtandi all face loss of exclusivity in the coming years. Eliquis was one of the biggest growth contributors this quarter, which means a large share of current growth comes from a drug that will eventually lose protection. The pipeline updates in the release, including positive Phase 3 data for Elrexfio in multiple myeloma, new FDA approvals for Talzenna with Xtandi and for Tukysa, and an EMA filing for a Lyme disease vaccine with Valneva, are the company’s answer to that gap.
For income-focused shareholders, Pfizer paid $7.3 billion in dividends, or $1.29 a share, in the first nine months, while making no buybacks despite $3.3 billion of authorisation remaining. The pattern is similar to other large drugmakers that have leaned on cost savings this year; FutureKnowledge covered a comparable approach in AstraZeneca’s Q3 results and its $1.5 billion savings plan.
Who is more or less exposed
- Businesses tied to COVID-19 products, such as contract manufacturers and distributors, face continued pressure: Pfizer CentreOne, its contract manufacturing unit, saw revenue fall 13% to $300 million.
- Oncology and specialty-care suppliers are in the growing part of Pfizer’s business, given the gains in Padcev, Lorbrena and other launched products.
- Vaccine-focused businesses remain exposed to lower US vaccination rates, which weighed on both Prevnar and Comirnaty this quarter.
- Payers and pricing: Eliquis growth was driven mainly by US net price, so US drug-pricing policy remains a key variable. The release refers to voluntary US agreements on drug costs and TrumpRx listings only in risk language, without quantifying any effect.
Scenarios to watch
The table below sets out conditional scenarios, not predictions.
| If this happens | Possible implication |
|---|---|
| Launched and acquired products keep growing at about 30% | Non-COVID growth could more fully offset COVID declines, making the top end of the $62bn-$64bn range more reachable |
| A weak US respiratory season further cuts Paxlovid and Comirnaty demand | Headline revenue could stay flat despite pipeline progress |
| US pricing policy changes affect net prices for products such as Eliquis | One of the quarter’s largest growth drivers could slow |
| Late-stage pipeline readouts such as Elrexfio translate into approvals | Investors may focus more on post-patent-cliff revenue than on COVID trends |
What to watch next
- Fourth-quarter COVID-19 product sales, which depend on the winter respiratory season.
- Any 2027 outlook, including the effect of expected generic competition and the productivity savings Pfizer has targeted for 2027 to 2029.
- Progress in the obesity programme, which the company said continued to advance but did not detail in the release.
- Whether Pfizer resumes share buybacks, which the 2026 guidance does not assume.
The quarter also lands in a busy week for large-cap results; see FutureKnowledge’s coverage of Apple’s record Q4 revenue and weaker margin outlook.
Bottom line
Pfizer’s third quarter was a guidance story more than a growth story. Sales were flat and reported profit fell, but non-COVID products grew 7%, newer medicines grew 32%, and the full-year revenue range moved up by $1.5 billion. The muted share reaction suggests investors are weighing that progress against the patent expiries ahead.
Method note
This analysis compared Pfizer’s third-quarter 2026 results release (as published on StockTitan) with reports and data from StockStory, Grafa, Rallies and Pomegra. Consensus figures differ slightly by provider; the $0.73 EPS estimate was consistent across sources, while revenue consensus was cited as $15.85bn (StockStory) and about $15.9bn (Pomegra). Company figures were taken from the release where sources differed.